Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Orvepitant · 1 trial · 1 indication
Area Under Curve (AUC)
| Arm | Type | Description |
|---|---|---|
| Orvepitant | EXPERIMENTAL | Orvepitant single 20mg dose |
| Orvepitant and itraconazole | EXPERIMENTAL | Orvepitant single 20mg dose in combination with repeat dose itraconazole |
| Name | Type | Description |
|---|---|---|
| Orvepitant | DRUG | Single oral dose |
| Itraconazole | DRUG | Once daily dosing for 10 days |
Key Inclusion Criteria: * male volunteers * judged to be in good health, based on the results of medical history, physical examination, vital signs, 12 lead ECG, and clinical laboratory findings * body weight greater than 50 kg and body mass index (BMI) within the range 18 to 30 kg/m2 (inclusive) ...
Orvepitant is an investigational small molecule being developed by cbdMD, Inc. (YCBD). It is currently in Phase 1 clinical development. The drug has been studied in a pharmacokinetic trial involving healthy male volunteers to assess how it interacts with other substances in the body.
Orvepitant is being studied for its pharmacokinetic properties in healthy male volunteers. The completed Phase 1 trial focused on understanding how the drug is processed in the body when exposed to itraconazole. Its intended therapeutic use has not been specified in available clinical trial information.
Orvepitant is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The company is conducting clinical research on this investigational small molecule drug candidate.
Orvepitant is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. One Phase 1 study has been completed, and no active trials are currently listed for this drug candidate.
Orvepitant has one completed clinical trial registered as NCT03535662. This Phase 1 study, titled 'A Pharmacokinetic Study of the Effect of Itraconazole Exposure to Orvepitant in Healthy Volunteers,' enrolled 16 healthy male participants in the United Kingdom. The trial was controlled but not randomized or double-blinded.
No alternative names for Orvepitant have been reported. The drug is identified by its single name in clinical trial registrations and development records. It is a distinct investigational compound being studied by cbdMD, Inc.